$1.32 Billion is the total value of Sofinnova Investments, Inc.'s 64 reported holdings in Q1 2022. The portfolio turnover from Q4 2021 to Q1 2022 was 0.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| KRTX | Karuna Therapeutics, Inc. | $247,631,000 | -3.2% | 1,953,077 | 0.0% | 18.79% | +25.8% | |
| NTRA | Natera Inc | $126,229,000 | -56.4% | 3,102,960 | 0.0% | 9.58% | -43.4% | |
| AVTE | Aerovate Therapeutics, Inc. | $68,897,000 | +55.5% | 3,758,686 | 0.0% | 5.23% | +102.0% | |
| ASND | Ascendis Pharma A/Sadr | $58,659,000 | -12.8% | 499,824 | 0.0% | 4.45% | +13.3% | |
| IWM | iShares Russell 2000 ETFput | $30,791,000 | -7.7% | 150,000 | 0.0% | 2.34% | +19.9% | |
| YMAB | Y-mAbs Therapeutics, Inc | $26,068,000 | -26.7% | 2,194,278 | 0.0% | 1.98% | -4.8% | |
| NXTC | Nextcure, Inc | $12,985,000 | -19.0% | 2,671,856 | 0.0% | 0.99% | +5.3% | |
| CMPI | Checkmate Pharmaceuticals Inc | $11,505,000 | +11.1% | 3,606,707 | 0.0% | 0.87% | +44.3% | |
| INZY | Inozyme Pharma, Inc. | $8,296,000 | -40.0% | 2,028,308 | 0.0% | 0.63% | -22.0% | |
| BOLT | Bolt Biotherapeutics, Inc. | $7,547,000 | -44.1% | 2,754,437 | 0.0% | 0.57% | -27.3% | |
| GRTX | Galera Therapeutics, Inc | $7,339,000 | -48.1% | 3,083,712 | 0.0% | 0.56% | -32.6% | |
| AKUS | Akouos, Inc. | $7,197,000 | -44.1% | 1,515,074 | 0.0% | 0.55% | -27.4% | |
| OBSV | ObsEva SA | $7,172,000 | -24.1% | 4,749,623 | 0.0% | 0.54% | -1.4% | |
| NCNA | Nucana Plcadr | $5,594,000 | -58.0% | 5,599,999 | 0.0% | 0.42% | -45.4% | |
| Nucana Plcordinary shares | $2,398,000 | -58.0% | 2,400,000 | 0.0% | 0.18% | -45.5% | ||
| SYBX | Synlogic Inc. | $1,380,000 | -0.8% | 574,972 | 0.0% | 0.10% | +29.6% | |
| PDSB | PDS Biotechnology Corporation | $883,000 | -23.5% | 142,635 | 0.0% | 0.07% | 0.0% | |
| FUSN | Fusion Pharmaceuticals Inc | $607,000 | +86.2% | 78,066 | 0.0% | 0.05% | +142.1% | |
| PODD | Insulet Corp | $284,000 | 0.0% | 1,066 | 0.0% | 0.02% | +29.4% |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2022-05-16
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| Natera, Inc. | 23 | Q3 2023 | 20.5% |
| Ascendis Pharma A/S | 23 | Q3 2023 | 27.9% |
| NuCana plc | 23 | Q3 2023 | 15.2% |
| Synlogic Inc. (fmrly Mirna) | 22 | Q2 2023 | 0.9% |
| Y-mAbs Therapeutics, Inc. | 21 | Q3 2023 | 6.5% |
| ObsEva SA | 20 | Q4 2022 | 11.0% |
| Nucana PLC | 19 | Q3 2023 | 9.7% |
| SYNDAX PHARMACEUTICALS INC | 19 | Q3 2023 | 2.2% |
| PDS Biotechnology Corporation | 19 | Q3 2023 | 0.1% |
| Karuna Therapeutics, Inc. | 18 | Q3 2023 | 27.1% |
View Sofinnova Investments, Inc.'s complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| OTONOMY, INC.Sold out | February 14, 2022 | 0 | 0.0% |
View Sofinnova Investments, Inc.'s complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-02-13 |
| 13F-HR | 2023-11-14 |
| 13F-HR | 2023-08-14 |
| 13F-HR | 2023-05-11 |
| 13F-HR | 2023-02-14 |
| 13F-HR | 2022-11-08 |
| 13F-HR | 2022-08-15 |
| 13F-HR | 2022-05-16 |
| 13F-HR | 2022-02-14 |
| SC 13G/A | 2022-02-14 |
View Sofinnova Investments, Inc.'s complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.